About Us

Text size
view with small font size
view with medium font size
view with large font size

General Manager's Statement Kazunobu Mikawa

Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. is a company integrating pharmaceutical development, production and sales, playing an important role in the globalization of Kyowa Hakko Kirin Co., Ltd. (headquartered in Japan). It is currently engaged in the core fields of Nephrology and Oncology, with featured products such as GRAN, ESPO and REGPARA.

We make full use of the resource advantages such as R&D and technical capability of Kyowa Hakko Kirin Co., Ltd. to actively promote the development of new drugs in China. We provide high-quality drugs and services continually and steadily by introducing global new products constantly, so as to make a contribution to the health and well-being of Chinese people.

Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. adheres to the principles of disclosure & transparency and compliance, actively performs the social responsibility and makes contribution to the society, so as to be a reliable company for our stakeholders. I would like to ask for your continued support now and in the future.

Company Profile

Kyowa Hakko Kirin China Pharmaceutical Co., Ltd., the wholly owned enterprise established in China by Kyowa Hakko Kirin Co., Ltd., is located in the Pudong Zhangjiang Hi-tech Park, with a total investment of 29.8 million dollars. Her predecessor, Kirin KunPeng (China) Bio-Pharmaceutical Co., Ltd., which was founded in June 1997, is the first high-tech bio-medicine program introduced since the establishment of the "National Shanghai Biotech & Pharmaceutical Industrial Base", and passed the national GMP certification of China. The company was officially changed its name to "Kyowa Hakko Kirin China Pharmaceutical Co., Ltd." in April 2012.

Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. is an incorporated enterprise having the functions of development, manufacture and marketing, it has a total of more than 220 employees at present, with a basic business scope covering almost the whole Chinese Mainland territory. Currently, the company possesses: recombinant human granulocyte colony-stimulating factor injection, recombinant human erythropoietin injection, cinacalcet hydrochloride tablets, re-packaging right of benidipine hydrochloride tablets and manufacture right of IVD (in vitro diagnosis).

We will always conform to the principles of disclosure & transparency and compliance, adhere to patient-centered care, actively introduce, develop and continuously and steadily supply high quality and high value-added drugs; we will also continue to improve infrastructure, strengthen talent cultivation and reinforcement of organization function, have the courage to challenge the risk to contribute more for the improvement and development of the medical industry in China and around the world. We also sincerely hope that society will give more support and encouragement to us.

To Page Top